Abstract

Multi-drug resistance (MDR) is a phenomenon by which tumor cells exhibit resistance to a variety of chemically unrelated chemotherapeutic drugs. The classical form of multidrug resistance is connected to overexpression of membrane P-glycoprotein (P-gp), which acts as an energy dependent drug efflux pump. P-glycoprotein expression is known to be controlled by genetic and epigenetic mechanisms. Until now processes of P-gp gene up-regulation and resistant cell selection were considered sufficient to explain the emergence of MDR phenotype within a cell population. Recently, however, "non-genetic" acquisitions of MDR by cell-to-cell P-gp transfers have been pointed out. In the present study we show that intercellular transfers of functional P-gp occur by two different but complementary modalities through donor-recipient cells interactions in the absence of drug selection pressure. P-glycoprotein and drug efflux activity transfers were followed over 7 days by confocal microscopy and flow cytometry in drug-sensitive parental MCF-7 breast cancer cells co-cultured with P-gp overexpressing resistant variants. An early process of remote transfer was established based on the release and binding of P-gp-containing microparticles. Microparticle-mediated transfers were detected after only 4 h of incubation. We also identify an alternative mode of transfer by contact, consisting of cell-to-cell P-gp trafficking by tunneling nanotubes bridging neighboring cells. Our findings supply new mechanistic evidences for the extragenetic emergence of MDR in cancer cells and indicate that new treatment strategies designed to overcome MDR may include inhibition of both microparticles and Tunneling nanotube-mediated intercellular P-gp transfers.

Highlights

  • The P-glycoprotein is expressed in many human cancers, where it contributes to multi-drug resistance phenomenon

  • P-glycoprotein and drug efflux activity transfers were followed over 7 days by confocal microscopy and flow cytometry in drug-sensitive parental MCF-7 breast cancer cells co-cultured with P-gp overexpressing resistant variants

  • Time-progressive acquisition of P-gp and efflux activity by sensitive cells in the presence of resistant variants can occur through intercellular P-gp transfers, a de novo expression of P-gp by MCF-7 may alternatively originate from MDR1/ABCB1 gene induction in response to various signaling factors secreted by co-cultures

Read more

Summary

Background

The P-glycoprotein is expressed in many human cancers, where it contributes to multi-drug resistance phenomenon. Our findings supply new mechanistic evidences for the extragenetic emergence of MDR in cancer cells and indicate that new treatment strategies designed to overcome MDR may include inhibition of both microparticles and Tunneling nanotube-mediated intercellular P-gp transfers. In cancers developing from tissues possessing a natively high MDR1/ABCB1 expression, the P-gp-mediated efflux of anticancer agents severely limits the efficacy of chemotherapy [10] In these tumors P-gp is, one of the major contributors to intrinsic multidrug resistance (MDR) [11]. Diverse mechanisms have been reported for contributing to MDR1/ABCB1 up-regulation, including genomic instability, genetic induction of upstream or downstream MDR1/ABCB1 promoters, in particular via the nuclear steroid and xenobiotic receptor, and epigenetic changes based on DNA methylation, histone acetylation, and microRNAome modifications [15,16,17,18,19,20]

The abbreviations used are
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call